Back

Empagliflozin improves metabolic profile and prevents myocardial and coronary dysfunction in diabetic rat hearts subjected to ischemia/reperfusion injury

31 August 2025 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Innovative therapeutic strategies to combat ischaemia-reperfusion injury and cardiac dysfunction Ischaemia, Infarction, Cardioprotection ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Associate Professor Rosalinda Madonna

University of Pisa, Pisa (Italy)

6 More presentations in this session

Presentation thumbnail
PPAR alpha-driven CISD2 upregulation by hesperetin protects against myocardial ischemia/reperfusion injury
Professor C. Yeh (Tao-Yuan, TW)
Abstract Slides Video
Presentation thumbnail
Empagliflozin preserves hemodynamics and left ventricular function in nephrectomized rats after ischemia-reperfusion injury: a potential direct cardioprotective effect of SGLT2 inhibitor
Doctor K. Akiyoshi (Kasukabe, JP)
Abstract Slides Video
Presentation thumbnail
Organic polydopamine nanoparticles ameliorate endothelial ischemia-reperfusion injury, increasing antioxidant defense and reducing inflammatory response
Doctor S. Babboni (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Activation of AMPK via inhibition of PAR2 limits myocardial ischemia-reperfusion injury
Doctor L. Li (Winnipeg, CA)
Abstract Slides Video
Presentation thumbnail
Novel first-in-class drug candidate protects from ischemia-reperfusion injury by targeting the SERCA2 complex
Mrs A. Calejo (Oslo, NO)
Abstract Slides Video

Access the full session

Session thumbnail
Innovative therapeutic strategies to combat ischaemia-reperfusion injury and cardiac dysfunction

The Event

Event poster

ESC Congress 2025

31 August 2025 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Investigating the effects of empagliflozin on myocardial metabolic and lipid profile in healthy and metabolic syndrome murine models following acute myocardial infarction
thumbnail
Congress Presentation
Empagliflozin preserves hemodynamics and left ventricular function in nephrectomized rats after ischemia-reperfusion injury: a potential direct cardioprotective effect of SGLT2 inhibitor
thumbnail
Congress Presentation
Empagliflozin improves diastolic function in obese ZSF1 rats by restoring the cardiac mitochondrial respiratory capacity.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources